A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness

Library

Our publications, clinical studies, reports and press releases.

From discovery to proof: a Translation Evidence Map for precision psychiatry

October 5, 2026

 | Publication

Precision psychiatry aims to improve individual-patient decisions by measuring clinically meaningful heterogeneity, not by privileging any one data type, biomarker, or analytical method. This Personal View proposes a Translation Evidence Map that stages claims, from Level 0 (defined use case or discovery-positioning statement) to Level 6 (post-deployment monitoring), linked to measurement reliability, generalisable inference, decision value, safe delivery, and proportionality to risk, clinical need, and inaction.

Inflammatory protein markers and treatment outcomes across mood and psychotic disorders: a systematic review and meta-analysis

July 9, 2026

 | Publication

Poor treatment outcomes worsen prognosis in schizophrenia, bipolar disorder (BD), and major depressive disorder (MDD) and likely involve shared mechanisms, including alterations in inflammatory protein markers. However, the role of these markers on treatment outcomes was not previously studied cross-diagnostically, and to fill this gap, we performed a systematic review and meta-analysis.

Effect of ketamine and esketamine on RNA expression and its relevance for depression: A systematic review

July 31, 2025

 | Publication

This systematic reviewed explored the changes in genic expression (transcriptional changes) associated with the application of ketamine and esketamine. These medications have shown a robust efficacy in the pharmacological management of treatment-resistant depression (TRD). Although the systematic review could not identify specific biomarkers associated with the use of these pharmacological treatments, transcriptional profiling revealed dynamic molecular responses to them. Such general transcriptional changes implicate neuroplastic, inflammatory, and metabolic pathways, laying the groundwork for a better understanding of the biological mechanisms underlying the antidepressant effects of ketamine and esketamine.

Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis

May 25, 2025

 | Publication

In this original research study, the authors applied a cutting-edge methodology to predict the proteome plasma levels in more than 3,500 major depressive patients. Leveraging this dataset, the authors studied the association of such protein predicted levels with non-response, non-remission, and treatment-resistant depression (TRD) in this cohort. Results identified several nominal associations between specific proteins and these treatment-related variables and suggested that immune-inflammatory and neuroplastic mechanisms could play a key role in treatment response in major depression.

Moving toward precision and personalized treatment strategies in psychiatry

April 21, 2025

 | Publication

In this review, the authors discuss the progress and the hurdles for the implementation of multimodal approaches for personalized treatment approaches in psychiatry. In this review, current status in the research of biological, clinical, and environmental predictors in schizophrenia, bipolar disorder, and major depression. Most recent findings in neuroimaging, EEG, proteomics, circadian biology, and genetics are discussed. The authors conclude that, despite the challenges for its implementation, precision psychiatry holds promise for the improvement of treatment effectiveness that would lead to better outcomes for these patients.

Transdiagnostic Effects of Schizophrenia Polygenic Scores on Treatment Outcomes in Major Psychiatric Disorders

March 15, 2025

 | Publication

Schizophrenia polygenic scores (SCZ PRS) represent the collective influence of many genetic variants, that individually have only small effects, on a person’s risk to develop schizophrenia (SCZ). They are studied as a predictor for many traits and outcomes in mental illness. In this review, the authors examine the association of SCZ PRS with treatment outcomes across SCZ, major depressive disorder (MDD), and bipolar disorder (BD). A higher SCZ PRS has been associated with poorer treatment outcomes, including treatment resistance or non-remission to antidepressants in MDD, poorer response to antipsychotics in SCZ, and lower lithium efficacy in BD. SCZ PRS are also associated with persistent negative symptoms, cognitive impairments, and long-term illness severity in SCZ. Currently, the predictive power of SCZ PRS alone it too small to be useful in clinical care. However, combining SCZ PRS with environmental factors, other biological information, and neuroimaging data could improve prediction models. Despite some variation in findings, the overall evidence suggests that SCZ PRS has a cross-diagnostic influence on disease progression and treatment outcomes and can be one important puzzle piece in the ongoing efforts towards precision psychiatry.

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe

December 27, 2024

 | Publication

In this article, the Psych-STRATA project is presented: a multidisciplinary initiative aimed at improving the early identification and treatment of treatment-resistant psychiatric disorders, including schizophrenia, bipolar disorder, and major depressive disorder. The project takes a comprehensive approach involving the identification of genetic and clinical biomarkers, testing early intensified pharmacological treatment in a randomized controlled trial, and developing machine learning models for personalized therapy. A shared decision-making framework, including a mental health board and digital tools is implemented, alongside patient empowerment efforts. Finally, drug repurposing and AI-driven treatment recommendations aim to advance personalized, evidence-based psychiatric care.

Unraveling epigenomic signatures and effectiveness of electroconvulsive therapy in treatment-resistant depression patients: a prospective longitudinal study

July 17, 2024

 | Publication

Electroconvulsive therapy (ECT) has been shown to be beneficial for patients with treatment-resistant depression (TRD). However very little is known about the biological underpinnings of this intervention. In order to obtain mechanistic insight on the effects of ECT, an epigenome-wide analysis was carried out 32 TRD patients who underwent ECT sessions. ECT-associated methylation changes were observed in several regions of the genome, some of them implicated in inflammatory/immune processes. This pilot study provides preliminary evidence of the epigenetic changes associated with ECT and confirms the role of inflammation and immune response in TRD.

Polygenic risk scores of lithium response and treatment resistance in major depressive disorder

September 28, 2023

 | Publication

In this article, the authors describe an increased genetic load for lithium treatment response in patients who suffer treatment-resistant depression (TRD) when compared to depressive patients without TRD (they respond well to antidepressant pharmacological treatment). On the other hand, TRD and non-TRD patients did not show differences regarding the genetic load for antidepressant treatment response. Taken together, these results describe the existence of a genetic profile of lithium-sensitivity in TRD that could explain the efficacy of lithium to treat TRD.

Genomic Stratification of Clozapine Prescription Patterns Using Schizophrenia Polygenic Scores

January 15, 2023

 | Publication

In this article, the authors observe that the genetic load for schizophrenia is associated with the highest clozapine dose in patients who suffer schizophrenia. It is noteworthy to mention that these researchers replicated this finding in 3 independent samples, the gold standard when it comes to validate the results of a genetic study.